Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MSL001
MIFTS: 61

Measles

Categories: Eye diseases, Infectious diseases, Rare diseases, Skin diseases, Smell/Taste diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Measles

About this section

MalaCards integrated aliases for Measles:

Name: Measles 11 19 75 28 53 41 2 43 14 16 71 31 33
Rubeola 19 75 33
Morbilli 11 33
Koplik Spots 33
Measles Nos 33

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Eye diseases Smell/Taste diseases Skin diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:8622
ICD9CM 34 055
MeSH 43 D008457
NCIt 49 C96406
SNOMED-CT 68 154338006
UMLS 71 C0025007
Sources

Summaries for Measles

About this section

MedlinePlus: 41 Measles is an infectious disease caused by a virus. It spreads easily from person to person. It causes a blotchy red rash. The rash often starts on the head and moves down the body. Other symptoms include: Fever Cough Runny nose Conjunctivitis (pink eye) Feeling achy and run down Tiny white spots inside the mouth Sometimes measles can lead to serious problems. There is no treatment for measles, but the measles-mumps-rubella (MMR) vaccine can prevent it. "German measles", also known as rubella, is a completely different illness. Centers for Disease Control and Prevention

MalaCards based summary: Measles, also known as rubeola, is related to rubella and subacute sclerosing panencephalitis, and has symptoms including fever, cough and conjunctivitis. An important gene associated with Measles is CD46 (CD46 Molecule), and among its related pathways/superpathways are Disease and Innate Immune System. The drugs BCG vaccine and Adjuvants, Immunologic have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and eye, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology: 11 A viral infectious disease that results in infection located in skin, has material basis in Measles virus, which is transmitted by contact with oronasal secretions, or semen of an infected person. The infection has symptom fever, has symptom cough, has symptom coryza, has symptom conjunctivitis, and has symptom maculopapular, erythematous rash.

GARD: 19 A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.

CDC: 2 Measles is a highly contagious virus that can lead to complications.

Wikipedia: 75 Measles is a highly contagious infectious disease caused by measles virus. Symptoms usually develop... more...
Sources

Related Diseases for Measles

About this section

Diseases related to Measles via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 966)
# Related Disease Score Top Affiliating Genes
1 rubella 32.9 TLR3 RIGI IL6 IL2 IL1B IFNB1
2 subacute sclerosing panencephalitis 32.9 TLR3 SLAMF1 IL6 IL2 IFNA1 IFIH1
3 mumps 32.0 TLR3 STAT1 IL6 IL2 IL1B IFNB1
4 croup 32.0 RIGI IL6 IFNB1 IFNA1 CD46
5 exanthem 31.9 IL6 IL2 IL1B IFNA1 IFIH1
6 encephalitis 31.5 TLR3 TLR2 RIGI IL6 IL1B IFNB1
7 chickenpox 31.5 TLR3 STAT1 IL6 IL2 IL1B IFNB1
8 conjunctivitis 31.5 TLR3 IL6 IL2
9 herpes zoster 31.3 TLR3 TLR2 IL2 IFNA1
10 poliomyelitis 31.3 TLR3 RIGI IRF3 IL6 IL2 IFNB1
11 pneumonia 31.3 TLR3 TLR2 IL6 IL1B
12 purpura 31.2 IL6 IL2 IL1B
13 crohn's disease 31.2 TLR2 IL6 IL2 IL1B
14 common cold 31.2 TLR3 IL6 IL2 IL1B IFNB1 IFNA1
15 haemophilus influenzae 31.1 TLR2 IL1B
16 otitis media 31.1 TLR2 IL6 IL2 IL1B
17 appendicitis 31.1 IL6 IL2 IL1B
18 aseptic meningitis 31.1 IL6 IL1B IFNA1
19 human immunodeficiency virus type 1 31.0 TLR3 IRF3 IL2 CD209 ADAR
20 meningitis 31.0 TLR2 IL6 IL2 IL1B CD46
21 diarrhea 31.0 RIGI IRF3 IL6 IL2 IL1B IFNB1
22 dengue disease 31.0 RIGI IL6 IFNB1 IFNA1 CD209
23 vaccinia 31.0 STAT1 IRF3 IL6 IL2 IFNB1 IFNA1
24 hepatitis a 30.9 TLR3 IL1B IFNA1
25 yellow fever 30.9 STAT1 RIGI IL6 IL1B IFNB1
26 inflammatory bowel disease 1 30.9 TLR2 IL6 IL1B
27 respiratory failure 30.9 TLR3 IL6 IL2 IL1B IFNB1 IFNA1
28 acquired immunodeficiency syndrome 30.9 IL6 IL2 IL1B IFNA1
29 inflammatory bowel disease 30.8 TLR3 TLR2 STAT1 IL6 IL2 IL1B
30 influenza 30.8 TLR3 RIGI IFNB1 IFNA1 EIF2AK2
31 viral infectious disease 30.8 TLR3 TLR2 STAT1 SLAMF1 RIGI IRF3
32 bronchitis 30.8 TLR2 STAT1 IL6 IL1B
33 japanese encephalitis 30.8 TLR3 RIGI IRF3 IFNB1 IFNA1 CD209
34 gastroenteritis 30.8 IL6 IL1B IFNA1
35 newcastle disease 30.7 TLR3 RIGI IRF3 IFNB1 IFNA1 EIF2AK2
36 herpes simplex 30.7 TLR3 STAT1 RIGI IRF3 IFNB1 IFNA1
37 ulcerative colitis 30.7 TLR2 IL6 IL2 IL1B
38 dengue virus 30.7 RIGI IFIH1 CD209
39 bacterial pneumonia 30.7 TLR2 IL6 IL1B IFNB1
40 chikungunya 30.6 TLR3 RIGI IL6 IL1B IFIH1 CD209
41 hepatitis 30.6 STAT1 RIGI IRF3 IFNB1 IFNA1 IFIH1
42 stomatitis 30.6 STAT1 RIGI IL6 IL2 IL1B IFNB1
43 viral encephalitis 30.6 TLR3 RIGI IRF3 IL6 IL1B IFNB1
44 hepatitis b 30.6 TLR3 TLR2 STAT1 RIGI IL6 IFNB1
45 lymphadenitis 30.6 IL6 IL1B CD209
46 pharyngitis 30.6 TLR2 IL6 IL1B
47 covid-19 30.6 IRF3 IL6 IL2 IL1B IFNB1
48 juvenile rheumatoid arthritis 30.5 IL6 IL2 IL1B
49 middle east respiratory syndrome 30.5 IRF3 IL6 IFNB1
50 tick-borne encephalitis 30.5 TLR3 IFNA1 CD209

Graphical network of the top 20 diseases related to Measles:



Diseases related to Measles
Sources

Symptoms & Phenotypes for Measles

About this section

Symptoms:

11
  • • fever
  • • cough
  • • conjunctivitis
  • • coryza
  • • maculopapular

UMLS symptoms related to Measles:


fever; pruritus; exanthema; koplik spots

GenomeRNAi Phenotypes related to Measles according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ADAR CD209 CD46 EIF2AK2 FCGR2B IFIH1
2 no effect GR00402-S-2 10.19 ADAR CD209 CD46 EIF2AK2 FCGR2B IFIH1

MGI Mouse Phenotypes related to Measles:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ADAR CD209 EIF2AK2 FCGR2B IFIH1 IFNAR2
2 immune system MP:0005387 10.21 ADAR CD209 EIF2AK2 FCGR2B IFIH1 IFNA1
3 neoplasm MP:0002006 10.16 EIF2AK2 IFNAR2 IFNB1 IL1B IL2 IL6
4 cellular MP:0005384 10.15 ADAR CD209 EIF2AK2 FCGR2B IFIH1 IL2
5 cardiovascular system MP:0005385 10.06 ADAR CD46 FCGR2B IL1B IL2 IL6
6 liver/biliary system MP:0005370 10.03 ADAR FCGR2B IFIH1 IL2 IL6 RIGI
7 hematopoietic system MP:0005397 9.91 ADAR CD209 EIF2AK2 FCGR2B IFIH1 IFNA1
8 respiratory system MP:0005388 9.81 FCGR2B IFNA1 IL2 IL6 IRF3 MSN
9 mortality/aging MP:0010768 9.47 ADAR CD209 EIF2AK2 FCGR2B IFIH1 IFNAR2
Sources

Drugs & Therapeutics for Measles

About this section

Drugs for Measles (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Approved, Investigational Phase 4
2 Adjuvants, Immunologic Phase 4
3 Liver Extracts Phase 4
4 Immunologic Factors Phase 4
5
Podophyllin Approved Phase 3 9000-55-9
6
Petrolatum Approved, Investigational Phase 3 8009-03-8
7
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
8
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
9
Sulfamethoxazole Approved Phase 3 723-46-6 5329
10 Orange Approved Phase 3
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8 5280382 445354
13 Keratolytic Agents Phase 3
14 Dermatologic Agents Phase 3
15 Folic Acid Antagonists Phase 3
16 Folate Phase 3
17 Vitamin B9 Phase 3
18 Antiprotozoal Agents Phase 3
19 Antiparasitic Agents Phase 3
20 Vitamin B Complex Phase 3
21 Antimalarials Phase 3
22 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
23 Cytochrome P-450 Enzyme Inhibitors Phase 3
24 Vitamins Phase 3
25 Retinol palmitate Phase 3
26 Somatomedin B Phase 3
27 Hemagglutinins Phase 3
28 Taxane Phase 3 108169
29 Trace Elements Phase 3
30 Micronutrients Phase 3
31
Altretamine Approved Phase 2 645-05-6 2123
32
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
33
Iodine Approved, Investigational Phase 2 7553-56-2 807
34
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
35
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
36
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
37
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
38
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
39
Ascorbic acid Approved, Nutraceutical Phase 2 50-81-7 54676860 54670067 5785
40 Antirheumatic Agents Phase 1, Phase 2
41 Alkylating Agents Phase 1, Phase 2
42 Antineoplastic Agents, Alkylating Phase 1, Phase 2
43 Immunoglobulins Phase 2
44 Antibodies Phase 2
45 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Anti-Bacterial Agents Phase 2
48 Anti-Infective Agents Phase 2
49 Immunoglobulins, Intravenous Phase 2
50 Immunosuppressive Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 A Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality and to Explore the Role of Maternal Measles Antibodies for the Beneficial Non-specific Effects of Measles Vaccine Unknown status NCT01486355 Phase 4
2 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children Unknown status NCT03330171 Phase 4
3 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01644721 Phase 4
4 A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau Unknown status NCT01668745 Phase 4
5 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
6 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) Unknown status NCT04638985 Phase 4
7 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine Completed NCT02325310 Phase 4
8 Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau Completed NCT00168571 Phase 4
9 Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
10 Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh Completed NCT01700621 Phase 4
11 Assessing Immunogenicity of Measles-Rubella Vaccine at 6 and 9 Months of Age Completed NCT03071575 Phase 4
12 Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines Completed NCT02643433 Phase 4
13 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
14 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
15 Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age Completed NCT00168662 Phase 4
16 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
17 Measles Vaccination in Guinea-Bissau. Strategies to Reduce Disease Burden and Improve Child Survival Completed NCT00168558 Phase 4
18 An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age Completed NCT00326183 Phase 4
19 Immunogenicity and Safety of AVAXIMâ„¢ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAXâ„¢ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children Completed NCT00313950 Phase 4
20 Comparison of Immunization Schedules of Beijing Tiantan Biological's MMR Vaccine in 18-72 Month-Old Children Completed NCT03160820 Phase 4
21 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
22 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age. Completed NCT01777529 Phase 4
23 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
24 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
25 The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age Completed NCT01306006 Phase 4
26 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
27 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Completed NCT04111432 Phase 4
28 Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting Completed NCT03780179 Phase 4
29 Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand Completed NCT02724852 Phase 4
30 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
31 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
32 Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination Completed NCT00244673 Phase 4
33 Specific and Non-specific Effects of Measles and BCG Vaccines for Mother and Child Recruiting NCT04899765 Phase 4
34 Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland Recruiting NCT01770119 Phase 4
35 A Phase IV Randomized, Blinded Clinical Trial to Assess Measles Mumps and Rubella Combined Vaccine, Live, (MMR) Lot-to-lot Consistency in Healthy Chinese Children at the Age of 8-12 Months Recruiting NCT05161845 Phase 4
36 Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live Active, not recruiting NCT05279248 Phase 4
37 A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children Active, not recruiting NCT03460002 Phase 4
38 Health Effects of Utilising Curative Health System Contacts to Provide Measles Vaccination - a Randomised Controlled Trial Enrolling by invitation NCT04220671 Phase 4
39 The Efficacy of Intralesional Measles, Mumps, Rubella (MMR) Vaccine, Intralesional Candidal Antigen and Topical Podophyllin in Treatment of Genital Warts: A Comparative Study Unknown status NCT03853785 Phase 3 Topical Podophyllin
40 Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life Completed NCT01681992 Phase 3
41 Prophylactic Antibiotics in Measles Infection. A Community-Based Randomised Double-Blind Placebo-Controlled Trial in Guinea-Bissau Completed NCT00168532 Phase 3 Sulfamethoxazole-Trimethoprim
42 Safety and Immunogenicity Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine, in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
43 Long-Term Assessment at 24 Months Post-Vaccination of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine to Measles Vaccine Given Alone Completed NCT00412516 Phase 3
44 Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Completed NCT04183114 Phase 2, Phase 3
45 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
46 Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®. Completed NCT00406211 Phase 3
47 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months Completed NCT00402831 Phase 3
48 An Immunogenicity and Safety Evaluation of Two Doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age Completed NCT00384397 Phase 3
49 Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Healthy Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
50 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762) Completed NCT02058563 Phase 3

Search NIH Clinical Center for Measles

Cochrane evidence based reviews: measles

Sources

Genetic Tests for Measles

About this section

Genetic tests related to Measles:

# Genetic test Affiliating Genes
1 Measles 28
Sources

Anatomical Context for Measles

About this section

Organs/tissues related to Measles:

FMA: Skin
MalaCards : Skin, Brain, Eye, Liver, Bone Marrow, Breast, Lung
Sources

Publications for Measles

About this section

Articles related to Measles:

(show top 50) (show all 25277)
# Title Authors PMID Year
1
Impact of the COVID-19 pandemic on timeliness and equity of measles, mumps and rubella vaccinations in North East London: a longitudinal study using electronic health records. 62 41
36456017 2022
2
Associations of the COVID-19 pandemic with the reported incidence of important endemic infectious disease agents and syndromes in Pakistan. 62 41
36435768 2022
3
Hesitant and anti-vaccination groups: A qualitative study on their perceptions and attitudes regarding vaccinations and their reluctance to participate in academic research- an example during a measles outbreak among a group of Jewish parents in Israel. 62 41
36438238 2022
4
Measles virus-induced immunosuppression in SLAM knock-in mice. 53 62
20200244 2010
5
Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. 53 62
20071568 2010
6
Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). 53 62
20042501 2010
7
Development and evaluation of a rapid immunochromatographic test for mumps-specific IgM in oral fluid specimens and use as a matrix for preserving viral nucleic acid for RT-PCR. 53 62
20087926 2010
8
Restriction analysis of otosclerosis-associated CD46 splicing variants. 53 62
19597833 2010
9
Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor. 53 62
19806178 2009
10
Laboratory confirmation of measles in elimination settings: experience from the Republic of the Marshall Islands, 2003. 53 62
19274360 2009
11
Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. 53 62
19007958 2009
12
Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesis. 53 62
19319188 2009
13
Disease-associated novel CD46 splicing variants and pathologic bone remodeling in otosclerosis. 53 62
18677279 2008
14
Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. 53 62
18715339 2008
15
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. 53 62
18559536 2008
16
Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. 53 62
18419254 2008
17
High-density rafts preferentially host the complement activator measles virus F glycoprotein but not the regulators of complement activation. 53 62
18455798 2008
18
Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. 53 62
18325643 2008
19
[Host genetic factors for the development of SSPE]. 53 62
17695285 2007
20
Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. 53 62
17695519 2007
21
Downregulation of human CD46 by adenovirus serotype 35 vectors. 53 62
17377598 2007
22
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. 53 62
17492596 2007
23
Expression of measles virus receptors in otosclerotic, non-otosclerotic and in normal stapes footplates. 53 62
17294206 2007
24
Current problems of measles control in Japan and Western Pacific Region. 53 62
17368662 2007
25
Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. 53 62
17356690 2007
26
Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. 53 62
17070884 2007
27
Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection. 53 62
17135325 2007
28
Detection of circulating antigen with a MAb-based sandwich-ELISA and its comparison with specific IgM detection in sera of patients with hemorrhagic fever with renal syndrome. 53 62
17316085 2007
29
A case of common variable immunodeficiency syndrome associated with Takayasu arteritis. 53 62
17304891 2007
30
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. 53 62
17133484 2006
31
Cloning, expression, and purification of a highly immunogenic recombinant gonadotropin-releasing hormone (GnRH) chimeric peptide. 53 62
17064933 2006
32
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. 53 62
17062694 2006
33
Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. 53 62
16645169 2006
34
The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. 53 62
16782388 2006
35
Identification of amino acid residues involved in the interaction between measles virus Haemagglutin (MVH) and its human cell receptor (signaling lymphocyte activation molecule, SLAM). 53 62
16889684 2006
36
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. 53 62
16728275 2006
37
Assessment of the performance of a definition of a suspected measles case: implications for measles surveillance. 53 62
16723063 2006
38
Immunosuppression caused by measles virus: role of viral proteins. 53 62
16237742 2006
39
Alterations in cell-mediated immune response in subacute sclerosing panencephalitis. 53 62
16223530 2005
40
Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. 53 62
16260741 2005
41
CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. 53 62
15920733 2005
42
Evaluation of diagnostic markers for measles virus infection in the context of an outbreak in Spain. 53 62
16207972 2005
43
Gene expression profiles in peripheral blood mononuclear cells from patients with subacute sclerosing panencephalitis using oligonucleotide microarrays. 53 62
16036810 2005
44
Localization of regions in CD46 that interact with adenovirus. 53 62
15919905 2005
45
CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. 53 62
15845515 2005
46
Rescue and propagation of fully retargeted oncolytic measles viruses. 53 62
15685166 2005
47
Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? 53 62
15659756 2005
48
Expression of the interferon-alpha/beta-inducible MxA protein in brain lesions of subacute sclerosing panencephalitis. 53 62
15337611 2004
49
Measles virus receptors: SLAM and CD46. 53 62
15248250 2004
50
Variation in vaccine response in normal populations. 53 62
15165177 2004
Sources

Variations for Measles

About this section
Sources

Expression for Measles

About this section
Search GEO for disease gene expression data for Measles.
Sources

Pathways for Measles

About this section

Pathways related to Measles according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Disease 66
Show member pathways
 13.78 TLR3 TLR2 STAT1 RIGI MSN IRF3
2
Innate Immune System 66
Show member pathways
 13.76 TLR3 TLR2 STAT1 RIGI MSN IRF3
3
TGF-Beta Pathway 64
Show member pathways
 13.53 STAT1 IL6 IL2 IL1B IFNB1 IFNAR2
4
SARS-CoV-2 Infection 66
Show member pathways
 13.25 TLR2 STAT1 RIGI IRF3 IFNB1 IFNAR2
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.23 ADAR EIF2AK2 IFNA1 IFNAR2 IFNB1 IL1B
6
PI3K-Akt signaling pathway 74
Show member pathways
 12.95 TLR2 IL6 IL2 IFNB1 IFNAR2 IFNA1
7
NF-KappaB Family Pathway 64
Show member pathways
 12.73 TLR3 TLR2 IL6 IL2 IL1B EIF2AK2
8
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.67 STAT1 IRF3 IL6 IL2 IL1B IFNB1
9
IL-1 Family Signaling Pathways 65
Show member pathways
 12.63 TLR2 STAT1 IL6 IL1B CD209
10
Immune response IL-23 signaling pathway 22
Show member pathways
 12.59 STAT1 IL6 IL2 IL1B EIF2AK2
11
Toll-Like receptor Signaling Pathways 65
Show member pathways
 12.56 TLR3 TLR2 IRF3 IL6 IL1B IFNB1
12
Interferon gamma signaling 66
Show member pathways
 12.54 STAT1 RIGI IRF3 IFNB1 IFNAR2 IFNA1
13
DDX58/IFIH1-mediated induction of interferon-alpha/beta 66
Show member pathways
 12.5 TLR3 RIGI IRF3 IFNB1 IFNA1 IFIH1
14
Bacterial infections in CF airways 22
Show member pathways
 12.44 TLR2 STAT1 IL6 IL1B IFNB1
15
Cytosolic sensors of pathogen-associated DNA 66
Show member pathways
 12.4 TLR3 RIGI IRF3 IL6 IL1B IFNB1
16
NF-kappaB Signaling 3
12.37 CD46 IFIH1 IFNA1 IL1B IL2 IRF3
17
Toll-like receptor signaling pathway 74
Show member pathways
 12.35 TLR3 TLR2 STAT1 SLAMF1 RIGI NECTIN4
18
Toll Comparative Pathway 64
Show member pathways
 12.34 IL1B IL6 IRF3 STAT1 TLR3
19
Colorectal Cancer Metastasis 64
12.2 IL6 STAT1 TLR2 TLR3
20
Antiviral mechanism by IFN-stimulated genes 66
Show member pathways
 12.18 STAT1 RIGI IRF3 EIF2AK2
21
Ebola virus infection in host 74
12.11 STAT1 RIGI IRF3 EIF2AK2 CD209
22
MAPK Pathway 70
Show member pathways
 12.06 TLR3 TLR2 STAT1 IL2 IL1B
23
Hematopoietic Stem Cells and Lineage-specific Markers 65
12.02 SLAMF1 IL6 IL2 CD209
24
IL27-mediated signaling events 61
Show member pathways
 11.95 TLR3 TLR2 STAT1 IL6 IL2 IL1B
25
Interferon Pathway 64
11.91 IFNA1 IFNAR2 IFNB1 IL6 STAT1
26
Th17 Differentiation 65
Show member pathways
 11.9 IL1B IL6 STAT1 TLR2 TLR3
27
Allograft rejection 74
11.85 STAT1 IL2 IL1B
28
Activation of NF-KappaB by PKR 64
Show member pathways
 11.84 IRF3 IL1B IFNB1 EIF2AK2
29
Acute viral myocarditis 74
11.8 TLR3 STAT1 IL6 IL2
30
Dendritic Cells Developmental Lineage Pathway 65
11.78 SLAMF1 IL6 IL2 IL1B IFNB1 CD209
31
Glucocorticoid receptor regulatory network 61
11.76 STAT1 IL6 IL2
32
Th17 cell differentiation pathway 74
11.76 STAT1 IL6 IL2 IL1B
33
Burn wound healing 74
11.75 IL6 IL1B IFNB1
34
Extrafollicular B cell activation by SARS-CoV-2 74
11.72 IL6 IL2 IFNAR2
35
Inflammatory bowel disease signaling 74
Show member pathways
 11.68 IL2 IL6 STAT1 TLR2
36
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.67 IL6 IL2 IL1B
37
Host-pathogen interaction of human coronaviruses - interferon induction 74
Show member pathways
 11.63 TLR3 TLR2 STAT1 RIGI IRF3 IFNB1
38
SHP2 signaling 61
11.6 STAT1 IL6 IL2
39
SARS-CoV-2 innate immunity evasion and cell-specific immune response 74
11.57 RIGI IRF3 IFNB1
40
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.57 STAT1 IL6 IFNAR2
41
Fibrin complement receptor 3 signaling pathway 74
11.53 TLR3 IRF3 IL6 IFNB1
42
Type II interferon signaling 74
11.45 STAT1 IL1B IFNB1 EIF2AK2
43
Mitochondrial immune response to SARS-CoV-2 74
Show member pathways
 11.43 RIGI IRF3 IL6
44
Cytokines and inflammatory response 74
11.33 IL6 IL2 IL1B IFNB1
45
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway 74
11.31 IRF3 IL6 IL1B
46
Prostaglandin signaling 74
11.27 IL6 IL1B IFNA1
47
Pathways of nucleic acid metabolism and innate immune sensing 74
10.92 RIGI IRF3 IFNB1 IFIH1 ADAR
48
mRNA vaccine activation of dendritic cell and induction of IFN-1 74
10.8 IFIH1 IRF3 RIGI TLR3
49
IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
10.78 IL6 IL1B
50
COVID-19 adverse outcome pathway 74
10.7 IL6 IL2
Sources

GO Terms for Measles

About this section

Biological processes related to Measles according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.6 TLR3 TLR2 STAT1 RIGI IRF3 IL6
2 positive regulation of gene expression GO:0010628 10.46 TLR3 TLR2 RIGI MSN IL6 IL1B
3 adaptive immune response GO:0002250 10.44 CD209 CD46 IFNA1 IFNB1 IL2 SLAMF1
4 innate immune response GO:0045087 10.41 TLR3 TLR2 SLAMF1 RIGI IRF3 IFIH1
5 immune response GO:0006955 10.37 TLR3 TLR2 IL6 IL2 IL1B FCGR2B
6 cytokine-mediated signaling pathway GO:0019221 10.33 STAT1 IL6 IL1B IFNB1 IFNAR2 IFNA1
7 cytosolic pattern recognition receptor signaling pathway GO:0002753 10.27 IFIH1 RIGI
8 cytosolic pattern recognition receptor signaling pathway GO:0039528 10.27 IFIH1 RIGI
9 positive regulation of tumor necrosis factor production GO:0032760 10.27 TLR3 TLR2 RIGI IL6 IFIH1
10 positive regulation of interleukin-6 production GO:0032755 10.27 IFIH1 IL1B IL6 RIGI TLR2 TLR3
11 positive regulation of inflammatory response GO:0050729 10.25 IL1B IL2 TLR2 TLR3
12 viral entry into host cell GO:0046718 10.24 CD209 CD46 NECTIN4 SLAMF1
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.24 TLR3 TLR2 IL6 IL1B EIF2AK2
14 positive regulation of interleukin-8 production GO:0032757 10.24 IL1B IL6 RIGI TLR2 TLR3
15 positive regulation of JNK cascade GO:0046330 10.23 TLR3 SLAMF1 IL1B FCGR2B
16 positive regulation of type II interferon production GO:0032729 10.22 IL1B IL2 SLAMF1 TLR3
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.2 TLR3 TLR2 IL1B EIF2AK2
18 positive regulation of T cell proliferation GO:0042102 10.18 IL6 IL2 IL1B CD46 CD209
19 type I interferon-mediated signaling pathway GO:0060337 10.18 STAT1 IRF3 IFNB1 IFNAR2 IFNA1
20 negative regulation of viral genome replication GO:0045071 10.16 IFNB1 IFIH1 EIF2AK2
21 positive regulation of chemokine production GO:0032722 10.16 TLR3 TLR2 IL6 IL1B EIF2AK2
22 positive regulation of interferon-beta production GO:0032728 10.16 IFIH1 IRF3 RIGI TLR2 TLR3
23 receptor signaling pathway via JAK-STAT GO:0007259 10.15 STAT1 IFNB1 IFNAR2
24 positive regulation of interleukin-10 production GO:0032733 10.14 TLR2 IL6 CD46
25 lipopolysaccharide-mediated signaling pathway GO:0031663 10.14 TLR2 IRF3 IL1B
26 defense response GO:0006952 10.13 FCGR2B IFNA1 IFNB1 STAT1 TLR3
27 response to virus GO:0009615 10.13 ADAR EIF2AK2 IFIH1 IFNAR2 IFNB1 RIGI
28 cellular response to interferon-beta GO:0035458 10.1 TLR3 STAT1 IFNB1
29 positive regulation of interferon-alpha production GO:0032727 10.07 TLR3 STAT1 RIGI IRF3 IFIH1
30 response to exogenous dsRNA GO:0043330 10.06 IFNA1 IFNB1 IRF3 RIGI TLR3
31 response to interferon-alpha GO:0035455 10.05 IFNAR2 EIF2AK2 ADAR
32 detection of virus GO:0009597 10.03 IFIH1 RIGI TLR3
33 positive regulation of cytokine production GO:0001819 10 EIF2AK2 IL1B IRF3 TLR3
34 positive regulation of response to cytokine stimulus GO:0060760 9.99 RIGI IFIH1
35 vascular endothelial growth factor production GO:0010573 9.99 IL6 IL1B
36 MDA-5 signaling pathway GO:0039530 9.96 IRF3 IFIH1
37 cellular response to exogenous dsRNA GO:0071360 9.96 TLR3 RIGI IRF3 IFNB1 IFIH1
38 positive regulation of toll-like receptor signaling pathway GO:0034123 9.95 TLR3 TLR2
39 immune system process GO:0002376 9.93 ADAR CD209 CD46 EIF2AK2 IFIH1 IL2
40 regulation of type III interferon production GO:0034344 9.92 RIGI IFIH1
41 cellular response to virus GO:0098586 9.86 TLR3 IRF3 IL6 IFNB1 IFNAR2 IFNA1
42 defense response to virus GO:0051607 9.7 ADAR EIF2AK2 IFIH1 IFNA1 IFNAR2 IFNB1
43 defense response to other organism GO:0098542 9.68 RIGI IFIH1

Molecular functions related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.85 IL6 IL2 IL1B IFNB1 IFNA1
2 virus receptor activity GO:0001618 9.56 SLAMF1 NECTIN4 CD46 CD209
3 double-stranded RNA binding GO:0003725 9.4 TLR3 RIGI MSN IFIH1 EIF2AK2 ADAR
Sources

Sources for Measles

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....